Compare OOMA & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | ANGO |
|---|---|---|
| Founded | 2003 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.2M | 420.2M |
| IPO Year | 2015 | 2004 |
| Metric | OOMA | ANGO |
|---|---|---|
| Price | $17.75 | $11.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $18.77 | $18.00 |
| AVG Volume (30 Days) | 220.1K | ★ 462.7K |
| Earning Date | 05-27-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | 81.92 |
| EPS | ★ 0.23 | N/A |
| Revenue | $114,490,000.00 | ★ $291,010,000.00 |
| Revenue This Year | $20.35 | $9.51 |
| Revenue Next Year | $4.17 | $4.96 |
| P/E Ratio | $71.00 | ★ N/A |
| Revenue Growth | 9.53 | ★ 10.17 |
| 52 Week Low | $9.79 | $8.36 |
| 52 Week High | $16.89 | $13.99 |
| Indicator | OOMA | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 80.02 | 56.42 |
| Support Level | $10.95 | $10.38 |
| Resistance Level | N/A | $11.81 |
| Average True Range (ATR) | 0.56 | 0.35 |
| MACD | 0.14 | 0.06 |
| Stochastic Oscillator | 98.71 | 90.48 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.